Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 503


The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.

Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G, Krex D.

J Neurooncol. 2012 Dec;110(3):325-33. doi: 10.1007/s11060-012-0977-2. Epub 2012 Sep 27. Erratum in: J Neurooncol. 2013 Jan;111(1):95. Schrok, E [corrected to Schrock, E].


Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.


IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.

Juratli TA, Kirsch M, Robel K, Soucek S, Geiger K, von Kummer R, Schackert G, Krex D.

J Neurooncol. 2012 Jul;108(3):403-10. doi: 10.1007/s11060-012-0844-1. Epub 2012 Mar 13.


Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.

Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M; German Glioma Network.

Clin Cancer Res. 2013 Sep 15;19(18):5146-57. doi: 10.1158/1078-0432.CCR-13-0017. Epub 2013 Aug 5.


Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55. doi: 10.3174/ajnr.A2950. Epub 2012 Feb 9.


MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.


Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.

Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.

Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22.


Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).

Leibetseder A, Ackerl M, Flechl B, Wöhrer A, Widhalm G, Dieckmann K, Kreinecker SS, Pichler J, Hainfellner J, Preusser M, Marosi C.

Neuro Oncol. 2013 Jan;15(1):112-21. doi: 10.1093/neuonc/nos283. Epub 2012 Dec 7.


IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.

Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, Schulz M, Hutter G, Hench J, Schucht P, Boulay JL, Mariani L.

Neuro Oncol. 2013 Apr;15(4):469-79. doi: 10.1093/neuonc/nos317. Epub 2013 Feb 13.


Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.

Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.

Neurology. 2013 Oct 22;81(17):1515-22. doi: 10.1212/WNL.0b013e3182a95680. Epub 2013 Sep 25.


Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.

Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, Jiang T.

Med Oncol. 2012 Jun;29(2):1292-6. doi: 10.1007/s12032-011-9901-4. Epub 2011 Mar 11.


IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.

Yang P, Zhang W, Wang Y, Peng X, Chen B, Qiu X, Li G, Li S, Wu C, Yao K, Li W, Yan W, Li J, You Y, Chen CC, Jiang T.

Oncotarget. 2015 Dec 1;6(38):40896-906. doi: 10.18632/oncotarget.5683.


Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.

Wang K, Wang YY, Ma J, Wang JF, Li SW, Jiang T, Dai JP.

Asian Pac J Cancer Prev. 2014;15(24):10893-8.


IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.

Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW.

Cancer. 2012 Jan 15;118(2):452-60. doi: 10.1002/cncr.26298. Epub 2011 Jun 29.


Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.

J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.


Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas.

Siegal T.

Adv Tech Stand Neurosurg. 2016;(43):91-108. doi: 10.1007/978-3-319-21359-0_4. Review.


Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients.

Zhang GB, Cui XL, Sui DL, Ren XH, Zhang Z, Wang ZC, Lin S.

J Neurooncol. 2013 Jun;113(2):251-8. doi: 10.1007/s11060-013-1102-x. Epub 2013 Mar 15.


O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications.

Kang SH, Park KJ, Kim CY, Yu MO, Park CK, Park SH, Chung YG.

J Neurooncol. 2011 Feb;101(3):477-86. doi: 10.1007/s11060-010-0267-9. Epub 2010 Jun 17.


Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.


Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, Chandler C, Brazil L, Sadler G, Beaney R, Sibtain N, King A, Bodi I, Jones C, Ashkan K, Al-Sarraj S.

Neuro Oncol. 2013 Dec;15(12):1635-43. doi: 10.1093/neuonc/not125. Epub 2013 Oct 24.

Supplemental Content

Support Center